This led them to speculate that in tumor cells where mutant beta-catenin is active, it might reduce the release of exosomes carrying important signals within the tumor microenvironment.

such as axin or β-catenin, which seem to be directed to the active site of GSK3 by the interaction of axin with GSK3 at a distinct binding site (bottom half of figure). So, drugs that bind to the ...

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality worldwide. Current treatment modalities are few or ...